UPMC Enterprises has contributed to a series B round for Sempre Health, which is building a platform to make drugs more affordable for patients.
Sempre Health, a US-based dynamic drug pricing platform, completed a $15m series B round yesterday backed by UPMC Enterprises, the commercialisation arm of University of Pittsburgh Medical Center, a health system closely aligned with the institution.
Blue Venture Fund, which invests on behalf of 35 members of health insurance group Blue Cross Blue Shield Association, led the round, which additionally attracted Rethink Impact, LifeForce Capital and Industry Ventures.
Founded in 2015, Sempre Health is building a platform that connects payers and pharmaceutical firms to sell medications to chronic disease patients. The platform automatically adjusts out-of-pocket costs by taking into account medication adherence and benefit design.
Anurati Mathur, CEO of Sempre Health, said: “We are thrilled to work with this accomplished group of healthcare investors who understand our partners, our marketplace, and our commitment to help people afford and take their medications as prescribed.
“The significance and value of Sempre’s distinctive approach has only grown given the current economic crisis we are facing due to the covid-19 pandemic.
“We look forward to working together with Blue Venture Fund and UPMC Enterprises as we embark on our next phase of growth and continue to fundamentally change medication affordability and access in the United States.”
Rethink Impact led an $8m series A round for Sempre Health in August 2018, when it was joined by Social Capital and unnamed others.
